The Edge of the Collaborative Practice Agreement

Clinical priority first, authority second. An INR of 5.8 with gum bleeding and melena is a suspected gastrointestinal bleed, not an asymptomatic high INR. The immediate obligation is to direct the patient to emergency evaluation now - not to manage a possible GI bleed by telephone, and not to wait until Monday for the physician.

What the agreement authorizes. The written agreement lets her manage and adjust warfarin, so she has authority to act within her protocol. But protocols typically authorize dose adjustment and monitoring intervals for out-of-range INRs without bleeding; they rarely authorize holding warfarin, ordering vitamin K, or ordering labs beyond the protocol's scope. Read the protocol before doing anything beyond what it expressly permits, and do not order reversal therapy on your own initiative unless the protocol says so.

Notification and coverage. Illinois collaborative practice does not suspend the physician's oversight; the agreement must specify how the physician is reached and who covers. Here the agreement names a covering physician - call that person. If the covering physician is also unreachable, the protocol's escalation pathway governs, and the emergency department referral stands on its own as the standard of care.

Drug interaction flag. Dronedarone inhibits CYP3A4 and P-glycoprotein and can raise warfarin exposure and INR; a new start two weeks ago is a plausible contributor. Communicate this to the ED and to cardiology, and document it. Identify the interaction, but do not let the explanation delay the referral.

Documentation. Time of contact, symptoms, INR, advice given, who was notified, and the disposition.

No. Her authority is defined entirely by the four corners of the written collaborative agreement plus the delegating physician's own scope. The agreement covers anticoagulation, statins, and INR/lipid ordering; it says nothing about thyroid replacement, and the levothyroxine was prescribed by an endocrinologist who has no relationship to this agreement at all.

Two separate reasons, both fatal:

1. Subject matter outside the delegation. A pharmacist under a collaborative agreement may do only what the agreement delegates. 'The patient needs it and the prescriber is away' does not expand the delegation.
2. Prescriber outside the agreement. Even if the agreement listed thyroid therapy, the collaborating physician cannot delegate authority over another prescriber's patient plan in a way that substitutes the pharmacist for the original prescriber. Continuing another prescriber's chronic therapy requires that prescriber, or an on-call covering prescriber, or the collaborating physician making an independent prescribing decision.

What she may legitimately do: help the patient reach the endocrinologist's on-call coverage; contact the endocrinology practice; document the request and the referral. If the collaborating physician were available and willing to prescribe the levothyroxine as an independent clinical decision within their own scope, that is the physician's prescription - not the pharmacist's delegated act.

Frame for the exam: collaborative practice authority is a ceiling, not a floor. The question is always 'does the written agreement delegate this act, for this prescriber's patients, with this oversight?' - and here it does not.

The burden is on the pharmacist to prove the authority existed at the moment she exercised it. She should be able to produce, on request:

• The signed written collaborative agreement, current and not expired, identifying the delegating physician, the delegated acts (anticoagulation management, statin titration, lab ordering), the protocols, the oversight and communication requirements, and the covering-physician arrangement.
• Evidence of her own qualifications - active Illinois pharmacist license and whatever training or experience the delegation requires for the specific authority claimed.
• A patient record showing what she did, when, on what data (INR value and date), what she communicated to whom, and the physician notification with a timestamp.
• Evidence of physician notification and review consistent with the frequency the agreement specifies. A collaborative agreement that is never operationalized - no notifications, no co-signatures, no review - is a paperwork problem that becomes a discipline problem.

What sank her case would be: acting outside the listed subject areas (levothyroxine), or exceeding the protocol on a bleeding patient without reaching any prescriber. Neither is curable by documentation afterward, so the note must also show that the escalation attempt happened. Verify the current statutory and rule citations for collaborative agreements in the Illinois Pharmacy Practice Act and its implementing rules before relying on any specific requirement in a real compliance review.